文献速递中枢神经肿瘤放疗

胶质母细胞瘤进展后放疗再程或全身治疗对生存的影响:NRG Oncology/RTOG 0525 二次分析

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-09-04

该研究为NRG Oncology/RTOG 0525三期临床试验的二次分析,纳入637例进展后且有治疗信息的胶质母细胞瘤患者,比较进展后未治疗、单纯放疗、单纯全身治疗及放疗联合全身治疗的总生存。结果显示未治疗者中位生存4.8个月,低于单纯放疗8.2个月、单纯全身治疗10.6个月和联合治疗12.2个月;校正混杂因素后全身治疗(无论是否联合放疗)与更好生存相关,各积极治疗组间无显著生存差异。

要点

  • 进展后未治疗者中位生存4.8个月,明显低于接受放疗、全身治疗或联合治疗者。
  • 校正混杂因素后,单纯放疗HR 0.74(95%CI 0.43-1.28),全身治疗HR 0.42(95%CI 0.34-0.53),联合治疗HR 0.44(95%CI 0.30-0.63)。
  • 单纯放疗与全身治疗(单用或联合)之间无显著生存差异。

核心结论

  • 胶质母细胞瘤进展后未接受挽救治疗者生存较差,但未治疗的选择可能反映预期预后更差。
  • 接受放疗、全身治疗或两者联合的患者之间无显著生存差异。

研究设计与样本

  • NRG Oncology/RTOG 0525三期临床试验的二次分析,评估新诊断胶质母细胞瘤剂量密集与标准剂量替莫唑胺。
  • 分析纳入637例进展且有治疗信息的患者,排除进展后半月内死亡者。

主要发现

  • 267例(42%)进展后未接受再程放疗或全身治疗,24例(4%)仅放疗,282例(44%)仅全身治疗,64例(10%)放疗联合全身治疗。
  • 未治疗者中位生存4.8个月,单纯放疗8.2个月,单纯全身治疗10.6个月,联合治疗12.2个月。
  • 校正混杂因素后,单纯放疗HR 0.74(95%CI 0.43-1.28),单纯全身治疗HR 0.42(95%CI 0.34-0.53),联合治疗HR 0.44(95%CI 0.30-0.63)。
  • 单纯放疗与全身治疗(单用或联合)之间无显著生存差异。

关键数值与推荐

  • 未治疗者中位生存4.8个月,单纯放疗8.2个月,单纯全身治疗10.6个月,联合治疗12.2个月。
  • 单纯放疗HR 0.74(95%CI 0.43-1.28),单纯全身治疗HR 0.42(95%CI 0.34-0.53),联合治疗HR 0.44(95%CI 0.30-0.63)。

临床怎么用

  • 胶质母细胞瘤进展后可考虑再程放疗、全身治疗或两者联合,未治疗者生存较差。
  • 选择挽救方案时需结合患者预期预后与耐受性,单纯放疗与全身治疗间未见显著生存差异。

局限性

  • 为二次分析,非随机比较,患者选择偏倚可能影响结果。
  • 未治疗组可能反映预期预后更差,混杂因素校正后仍不能完全排除选择偏倚。
  • 再程放疗在胶质母细胞瘤进展后的作用尚待正在进行的临床试验明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma. METHODS AND MATERIALS: This analysis of patients from Trial RTOG 0525 investigated the effect of reirradiation or systemic treatment after tumor progression. Survival from first progression was compared between patients receiving no therapy, systemic therapy alone, radiation alone, and both modalities. The Cox proportional hazards model was used to compare the mortality hazard, controlling for potential confounders. RESULTS: The analysis included 637 patients who progressed and had information on their management, excluding those who died less than half a month after progression. A total of 267 patients (42%) received neither reirradiation nor systemic treatment at progression, 24 (4%) received radiation alone, 282 (44%) received systemic treatment only, and 64 (10%) received both radiation and systemic therapy. Patients who received no treatment had a median survival of 4.8 months, lower than with radiation treatment alone (8.2 months), systemic therapy alone (10.6 months), and both radiation and systemic therapy (12.2 months). In survival models controlling for potential confounders, those who received radiation alone had modestly better survival (hazard ratio HR 0.74, 95% confidence interval [CI] 0.43-1.28), whereas those who underwent systemic therapy either without (HR 0.42, 95% CI 0.34-0.53) or with radiation therapy (HR 0.44, 95% CI 0.30-0.63) had better survival. There was no significant survival difference between patients who received radiation only and those who received systemic therapy (either with radiation or alone). CONCLUSIONS: Patients who received no salvage treatment had poorer survival than those who received radiation, chemotherapy, or the combination. However, patient selection for no treatment likely reflects poorer expected prognosis. There was no significant survival difference among those receiving radiation therapy, systemic therapy, or both. Ongoing clinical trials will help define the role of reirradiation after glioblastoma progression.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shi W, Scannell Bryan M, Gilbert MR, et al. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys. 2017. PMID: 29102648. doi:10.1016/j.ijrobp.2017.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。